All Dr Christopher Haqq (Elicio) articles
-
ReportBeyond the lab: vaccine development
This report provides insights into current research and future prospects from potential breakthroughs to global collaboration in pandemic preparedness.
-
ArticleThe future of cancer immunotherapy with Elicio Therapeutics
In this exclusive interview with Dr Christopher Haqq, Executive Vice President, Head of Research and Development, and Chief Medical Officer of Elicio Therapeutics, we explore the latest in Cancer Immunology Research. The study highlights the promising preclinical data demonstrating the potential of TCR-T cell therapy in combination with lymph node-targeted ...


